SecBot SecBot
SECBOTREPLAY Home › Report › SPRO

SPRO · Spero Therapeutics and GSK announced FDA approval of Utebzi (tebipenem…

Spero Therapeutics, Inc. · 8-K filed Jun 22, 2026 at 16:05 ET

At the news

BULLISHIMPACT 8/10

8-K filed Jun 22, 2026 at 16:05 ET

Spero Therapeutics and GSK announced FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for complicated UTIs in adults. The approval is based on the PIVOT-PO Phase III trial showing non-inferiority vs IV imipenem-cilastatin. The drug is expected to be available in the US by end of 2026. This is a major product approval for Spero, a clinical-stage biopharma with a $132M market cap, and validates its partnership with GSK.

  • FDA approved Utebzi (tebipenem pivoxil) for cUTIs including pyelonephritis on June 17, 2026
  • First and only oral carbapenem antibiotic approved in the US
  • Approval based on PIVOT-PO Phase III trial demonstrating non-inferiority vs IV imipenem-cilastatin (adjusted treatment difference: -1.3%; 95% CI: -7.5%, 4.8%)
  • More than 3 million cases of cUTIs treated annually in the US; a third of patients impacted by resistant infections

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access